OXY

Inspira™ Technologies Announces First in Human of HYLA™ Blood Sensor in Clinical Study

Retrieved on: 
Wednesday, March 22, 2023

RA'ANANA, Israel, March 22, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced today the first in human of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center, Israel.

Key Points: 
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a company aiming to revolutionize acute respiratory care, has announced today the first in human of a patient undergoing open-heart surgery in the HYLA research clinical study at Sheba Medical Center, Israel.
  • The HYLA Blood sensor is a non-invasive optical blood sensor, being developed using machine learning based algorithms to measure blood key parameters, continuously and in real-time during extracorporeal procedures including VV-ECMO, VA-ECMO and open-heart surgery.
  • The HYLA sensor measurements are designed to alert physicians of sudden changes in a patient's blood key parameters, as well as alert perfusionists of sudden changes in oxygenator performance and blood recirculation.
  • The HYLA research clinical study is a first in human study designed to compare parameters measured by the non-invasive HYLA sensor to a standard blood gas analyzer that requires blood draw from the patient.

Thinking about trading options or stock in Crowdstrike, Occidental Petroleum, Apple, Advanced Micro Devices, or General Electric?

Retrieved on: 
Wednesday, March 8, 2023

NEW YORK, March 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRWD, OXY, AAPL, AMD, and GE.

Key Points: 
  • NEW YORK, March 8, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRWD, OXY, AAPL, AMD, and GE.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report – Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

MicroSectors™ Launches Energy Long & Short Exchange Traded Notes on NYSE Arca

Retrieved on: 
Tuesday, February 14, 2023

NEW YORK, Feb. 14, 2023 /PRNewswire/ - REX Shares, LLC ("REX") today announced the launch of two new MicroSectors Exchange Traded Notes ("ETNs") issued by Bank of Montreal ("BMO"), linked to the Solactive MicroSectors™ Energy Index.

Key Points: 
  • NEW YORK, Feb. 14, 2023 /PRNewswire/ - REX Shares, LLC ("REX") today announced the launch of two new MicroSectors Exchange Traded Notes ("ETNs") issued by Bank of Montreal ("BMO"), linked to the Solactive MicroSectors™ Energy Index.
  • MicroSectors Energy 3x Leveraged ETNs (ticker: WTIU ) and MicroSectors Energy -3x Inverse Leveraged ETNs (ticker: WTID ) will start trading tomorrow on NYSE Arca.
  • The Solactive MicroSectors Energy Index, launched in January 2023, tracks the performance of 12 highly liquid, U.S. stocks from the energy and oil sector.
  • "The energy ETNs will provide investors with exposure to 12 highly liquid companies that are at the forefront of global energy trends," Acheychek added.

Inspira™ Technologies Receives Approval from Sheba Medical Center to Conduct Clinical Study of the HYLA™ Blood Sensor

Retrieved on: 
Monday, February 13, 2023

RA'ANANA, Israel, Feb. 13, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company creating new acute respiratory care technologies, announced today that it has received approval by the Ethics Committee at Sheba Medical Center in Israel to conduct a clinical study of its HYLA blood sensor in patients undergoing open-heart surgery. The study is planned to commence in the first quarter of 2023.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a company creating new acute respiratory care technologies, announced today that it has received approval by the Ethics Committee at Sheba Medical Center in Israel to conduct a clinical study of its HYLA blood sensor in patients undergoing open-heart surgery.
  • The HYLA blood sensor is a non-invasive optical blood sensor being developed using machine learning based algorithms to measure blood parameters, intended to provide continuous measurements in real-time during extracorporeal procedures.
  • The purpose of the clinical study is to assess the correlation of blood parameters measured by the HYLA blood sensor versus a standard blood gas analyzer results.
  • The HYLA blood sensor, as part of the INSPIRA ART system or ALICE Device, will allow for patient blood oxygenation while displaying continuous key blood measurements in real-time.

Inspira™ Technologies Granted Patent by U.S. Patent Office for the INSPIRA™ ART System's Convertible Dual Lumen Cannula Device and Method of Use

Retrieved on: 
Monday, January 23, 2023

RA'ANANA, Israel, Jan. 23, 2023 /PRNewswire/ -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the novel convertible dual lumen cannula device and method of use, being developed for the INSPIRA™ ART System, has been granted a patent by the U.S. Patent and Trademark Office (USPTO). The patent approval includes 20 claims that were found to be novel, with inventive step and industrial applicability.

Key Points: 
  • The Company expects to integrate the convertible dual lumen cannula with additional Inspira products in the future.
  • In addition, the Company may consider the future commercialization of the convertible dual lumen cannula separately as a disposable product.
  • Inspira Technologies' convertible dual lumen cannula device uniquely intravascularly converts a single-lumen cannula into a dual lumen cannula after initial insertion, thus allowing for the same incision point to potentially have multiple uses.
  • The Inspira Technologies convertible dual lumen is designed to potentially allow for fast action and reduced risk, complications and additional infection points.

Whitestone REIT Adds Lake Woodlands Crossing to its Houston Portfolio

Retrieved on: 
Thursday, December 22, 2022

HOUSTON, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced the acquisition of Lake Woodlands Crossing, a 60,246 square foot retail property in The Woodlands, TX.

Key Points: 
  • HOUSTON, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Whitestone REIT (NYSE:WSR) (“Whitestone” or the “Company”) today announced the acquisition of Lake Woodlands Crossing, a 60,246 square foot retail property in The Woodlands, TX.
  • “Lake Woodlands Crossing is a high-traffic center and benefits from a 1-mile radius average household income in excess of $250,000.”
    “Whitestone, headquartered in Houston, now owns 57 open-air retail centers located in some of the fastest-growing markets in the country.
  • Lake Woodlands Crossing is at the heart of The Woodlands, across from Market Street—a luxury brand, walkable outdoor shopping center anchored by powerhouse Texas grocer H-E-B.
  • This acquisition brings our Houston portfolio to 14 properties and allows us to leverage our in-place leasing, property management and construction teams,” said Whitestone REIT Chief Executive Officer, Dave Holeman.

Inspira™ Technologies Signs Strategic OEM Agreement with Terumo Cardiovascular

Retrieved on: 
Wednesday, December 28, 2022

RA'ANANA, Israel, Dec. 28, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of Terumo Corporation, a leading global medical device company. Terumo Corporation operates in over 160 countries and regions around the world, providing patients in a variety of medical settings with over 50,000 products and services.

Key Points: 
  • Terumo Cardiovascular is a division of Terumo Corporation, a leading medical device company operating in 160+ countries and regions
    RA'ANANA, Israel, Dec. 28, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N.
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of Terumo Corporation, a leading global medical device company.
  • Terumo Corporation operates in over 160 countries and regions around the world, providing patients in a variety of medical settings with over 50,000 products and services.
  • Terumo Cardiovascular are experts in the field of oxygenation systems, heart-lung machines and monitoring systems.

Inspira™ Technologies Signs Strategic OEM Agreement with Terumo Cardiovascular

Retrieved on: 
Tuesday, December 27, 2022

RA'ANANA, Israel, Dec. 27, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of Terumo Corporation, a leading global medical device company. Terumo Corporation operates in over 160 countries and regions around the world, providing patients in a variety of medical settings with over 50,000 products and services.

Key Points: 
  • Terumo Cardiovascular is a division of Terumo Corporation, a leading medical device company operating in 160+ countries and regions
    RA'ANANA, Israel, Dec. 27, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N.
  • Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that it has signed an exclusive OEM (Original Equipment Manufacturing) agreement with Terumo Cardiovascular, a division of Terumo Corporation, a leading global medical device company.
  • Terumo Corporation operates in over 160 countries and regions around the world, providing patients in a variety of medical settings with over 50,000 products and services.
  • Terumo Cardiovascular are experts in the field of oxygenation systems, heart-lung machines and monitoring systems.

Inspira™ Technologies Interview to Air on Bloomberg U.S. on the RedChip Money Report®

Retrieved on: 
Thursday, December 22, 2022

ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N.

Key Points: 
  • ORLANDO, Fla, Dec. 22, 2022 /PRNewswire/ -- RedChip Companies will air an interview with Inspira™ Technologies OXY B.H.N.
  • Ltd. (Nasdaq: IINN) ( Nasdaq: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, on The RedChip Money Report® on Bloomberg TV, this Saturday, December 24, at 7 p.m. Eastern Time (ET).
  • The RedChip Money Report® is produced by RedChip Companies Inc., an international investor relations and media firm with 30 years' experience focused on Discovering Tomorrow's Blue Chips Today™.
  • "The RedChip Money Report®" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies.

Inspira™ Technologies Begins Manufacturing of the ALICE™ CPB Device, ahead of planned 2023 FDA submission

Retrieved on: 
Tuesday, December 20, 2022

RA'ANANA, Israel, Dec. 20, 2022 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN) (NASDAQ: IINNW) (the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that it has begun the manufacturing process for the ALICE CPB (Cardiopulmonary Bypass) device (the "ALICE device") to undergo the Verification and Validation phase prior to its planned 2023 submission to the U.S. Food and Drug Administration (FDA) for 510(k) clearance. If FDA clearance is obtained, the ALICE device production line will be extended for Low-Rate Initial Production (LWRIP), which is an important operational stage in developing infrastructure to support serial manufacturing, quality control and shipping. Additional units are expected to be assembled for the targeted future first deployments of the ALICE devices in the U.S. and Israel.

Key Points: 
  • If FDA clearance is obtained, the ALICE device production line will be extended for Low-Rate Initial Production (LWRIP), which is an important operational stage in developing infrastructure to support serial manufacturing, quality control and shipping.
  • Additional units are expected to be assembled for the targeted future first deployments of the ALICE devices in the U.S. and Israel.
  • This includes full turn-key manufacturing, full system integration, including PCB (Printed Circuit Board) manufacturing, assembly services, testing and packaging in facilities that meet Good Manufacturing Practices (GMP) compliance.
  • The ALICE device is intended to be indicated for use in clinical settings requiring CPB support.